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Abstract
Background: Hepatoma up-regulated protein (HURP) is a component of the chromatin-dependent pathway for spindle
assembly. We examined the prognostic predictive value of HURP in human hepatocellular carcinoma (HCC).
Methods: HURP expression was evaluated by immunocytochemistry of fine needle aspirated hepatoma cells in 97 HCC
patients with Barcelona Clinic Liver Cancer (BCLC) stage A. Subsequently, these patients underwent partial hepatectomy
(n=18) or radiofrequency ablation (n=79) and were followed for 2 to 35 months. The clinicopathological parameters were
submitted for survival analysis.
Results: HURP expression in aspirated HCC cells was detected in 19.6% patients. Kaplan-Meier survival analysis showed that
positive HURP expression (P=0.023), cytological grading $3( P=0.008), AFP $35 ng/mL (P=0.039), bilirubin $1.3 mg/dL
(P=0.010), AST $50 U/L (P=0.003) and ALT $35 U/L (P=0.005) were all associated with a shorter disease-free survival. A
stepwise multivariate Cox proportional hazard model revealed that positive HURP expression (HR, 2.334; 95% CI, 1.165–
4.679, P=0.017), AST $50 U/L (HR, 3.697; 95% CI, 1.868–7.319, p,0.001), cytological grade $3 (HR, 4.249; 95% CI, 2.061–
8.759, P,0.001) and tumor number .1 (HR, 2.633; 95% CI, 1.212–5.722, P=0.014) were independent predictors for disease-
free survival. By combining the 4 independent predictors, patients with different risk scores (RS) showed distinguishable
disease-free survival (RS#1 vs. RS=2, P=0.001; RS=2 vs. RS=3, P,0.001). In contrast, the patients cannot be separated into
prognosis distinguishable subgroups by using AJCC/UICC TNM staging system.
Conclusion: HCC patients with BCLC stage A can be separated into three prognosis-distinguishable groups by use of a risk
score that is based upon HURP expression in aspirated HCC cells, ALT, cytological grade and tumor number.
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Introduction
Using an integrative bioinformatics approach to analyze
sequence tags expressed in human liver, a novel cell cycle
regulated gene named hepatoma up-regulated protein (HURP)
was identified 10 years ago [1]. HURP, expressed abundantly in
human hepatocellular carcinoma (HCC, ie. hepatoma), is a
mitotic phosphoprotein substrate for Aurora-A [2]. Aurora-A is a
cell cycle-regulated serine/threonine kinase that displays peak
levels of expression during the G2/M phase [3,4]. The fact that
the levels of HURP fluctuate during the cell cycle and reach a peak
at G2/M suggests that it plays a role in cell cycle regulation [5].
Further studies have indicated that HURP is a component of the
chromatin-dependent pathway for spindle assembly. It has a
crucial role in chromatin-induced microtubule assembly, stabilizes
and bundles K-fibers, and is essential for de novo microtubule
production from chromosomes [6]. Additionally, its activity is
required for proper kinetochore capture, efficient chromosome
congression, and timely mitotic progression. Defects in these
processes can trigger inappropriate anaphase initiation and
genomic instability [7,8]. Aside from transcriptional regulation,
intracellular abundance of HURP is also regulated by Cdk1/
cyclin B at the posttranslational level [9,10]. However, there may
be some redundant pathways compensating for the function of
HURP in the cell cycle as HURP (2/2) mice develop normally
and are indistinguishable from their wild-type littermates. The
only documented phenotype for HURP (2/2) mice is that female
mice are unable to form implantation sites due to an inability to
undergo the decidual reaction [11].
Despite the experimental data indicating a link between cell
cycle dysregulation and HURP aberrance, no convincing evidence
has been established to date suggesting a direct oncogenic role of
HURP in HCC. However, pieces of evidence implicating an
oncogenic potential of HURP were sporadically reported. Positive
HURP expression was associated with the emergence and
recurrence of transitional cell carcinoma [12,13]; gene expression
analysis revealed that HURP represented a prognosis marker
capable of distinguishing between benign and malignant adreno-
cortical tumors [14,15]; and in 293T cell lines (American Type
Culture Collection (ATCC) Manassas, VA, USA), overexpression
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apoptosis that is normally induced by serum starvation [16]. On
the other hand, the HURP gene is capable of enhancing the
chemosensitivity of deoxycytosine analogs in NIH3T3 cells [17],
and the viral protein HBx activates the expression of HURP to
prevent apoptosis during cancer progression and establishment of
chemoresistance in Hep3B cells [18].
HCC accounts for 90% of primary liver neoplasms, represents
the fifth most common cancer in the world, and is the third leading
cause of cancer-related death worldwide [19,20]. A precise staging
of the disease may help clinicians to understand the prognosis and
make the right choice of therapeutic modalities to benefit patients.
Currently, there are several prognostic scoring systems that have
been established using different clinicopathological variables [21].
However, even between patients at the same stage of HCC and
categorized by the same scoring system, the post-therapeutic
prognosis is still diverse. This is most likely due to the fact that
HCC is a multi-etiological disease with complex underlying
pathogenic mechanisms caused by a variety of risk factors.
Presumably, inclusion of good molecular markers in a prognostic
prediction system may remedy these insufficiencies and improve
the current staging methods [22]. Owing to the availability of
ultrasound examination as well as other sophisticated imaging
methods, an increasing number of HCCs are detected at an early
stage. Furthermore, to minimize the invasiveness of the proce-
dures, pathological diagnosis is gradually replaced by cytology
through fine needle aspiration. In addition, surgical resection is
being replaced largely by radiofrequency ablation (RFA) because
of the comparable therapeutic effectiveness between the two
treatments. Cytological characteristics of HCC cells, including
differentiation grading and immunostaining of specific antigens,
are easily obtained from fine needle aspiration. These parameters
are currently not included in any of the scoring systems, but they
may provide important information for effective prognosis
prediction. Though HURP was first mined from the database of
human HCC up-regulated genes, its role in human HCC in vivo
has remained elusive. To address this, we have established an
immunohistochemistry staining method to detect HURP expres-
sion in aspirated HCC cells from patients. The clinicopathologic
features, cytological grading and HURP expression in HCC cells
were all taken into account to calculate the prognostic predictors
in these HCC patients.
Materials and Methods
Patients
This was a single center, prospective prognostic study that was
conducted after approval by the Institutional Review Board at
Chang Gung Medical Center. Written informed consent was
obtained from all participants before inclusion. From November
2007 through December 2009, 97 consecutive patients (62 males
and 35 females), who were diagnosed to have HCC by aspiration
cytology and at least two dynamic imaging studies (dynamic
computed tomography and angiography), were included in the
study. These patients either met the criteria for RFA treatment
[23] or had localized HCCs and were suitable for surgical removal
of tumors. Blood biochemistries for the following parameters were
assayed: aspartate aminotransaminase (AST, ,34 U/L), alanine
aminotransaminase (ALT, ,36 U/L), total bilirubin (Bil,
,1.3 mg/dL), alpha-fetoprotein (AFP, ,15 ng/mL), albumin
(3.5–5.5 g/dL), Prothrombin time (10–13 seconds), creatinine
(F:0.44–1.03, M:0.64–1.27 mg/dL). Hepatitis B virus surface
antigens (HBsAg) were assayed by a commercially available
radioimmunoassay kit (Ausria-II, HBsAg-RIA; Abbott Laborato-
ries, North Chicago, IL). Antibodies to Hepatitis C virus (HCV
Ab) were assayed using a third-generation enzyme immunoassay
(Ax SYM HCV III, Abbott Laboratories, North Chicago, IL).
Additionally, the following clinicopathological data were also
recorded: gender, age, presence of liver cirrhosis, alcohol usage,
Edmondson’s cytological grade, number of tumors, largest tumor
size, presence of ascites upon therapy, date of therapy (RFA or
surgery), date of tumor recurrence, and date of last follow-up or
HCC related death. In our medical center, patients with main
portal vein thrombosis were excluded from surgical or ablation
therapy.
Liver aspiration to diagnose HCC
Under ultrasonographic guidance, a 21- or 22-gauge percuta-
neous transhepatic cholangiogram needle was used for aspiration
cytology. The air-dried smears were immediately stained with
Riu’s method [24]. Grading of HCC was made by Edmondson
and Steiner’s classification [25]. If the specimen was insufficient or
difficult for cytological diagnosis, an immediate liver biopsy for
pathologic examination was undertaken [26].
HURP immunocytochemistry
Mouse anti-HURP antibodies were kindly provided by Prof.
Chou CK (Yang-Ming University, Taiwan). The specificity and
sensitivity of these antibodies have been characterized in previous
publications [1,11,16,27]. HURP-positive and negative HCC
tissues (according to Western blot analysis) were used as controls
for each batch of staining. Normal macrophages, lymphocytes,
and granulocytes in the cell smears were used as internal negative
controls. Aspirated HCC cells were fixed in pure methanol.
Hepatocyte expression of HURP was assessed by the avidin-biotin
immunoperoxidase method. The slides were incubated in
Phosphate buffered saline (PBS) containing 3% hydrogen peroxide
for 20 minutes and were subsequently washed twice (5 minutes
each) in PBS containing 0.025% Triton X-100 (Sigma Chemical
Co., St. Louis, MO). The slides were then incubated with 10%
normal horse serum for 30 minutes, followed by an incubation
with a 1:500 dilution of the mouse anti-HURP antibody at 37uC
for 1 hour. After being washed with phosphate-buffered saline
(PBS; 0.1 M, pH 7.4), the sections were subsequently incubated
with biotin-conjugated horse anti-mouse immunoglobulins (Jack-
son Immunoresearch Lab., West Grove, PA) at a 1:400 dilution for
40 minutes. After being rinsed with PBS, sections were treated
with avidin-biotin complex (Vectastain Elite ABC Kit, Vector
Labs, CA) for 30 minutes and then incubated in a diaminoben-
zidine solution (DAB, Vector Labs, CA) for 1 minute. Nuclear
counterstaining was performed with hematoxylin.
Tumor Ablation
The patients were treated with the internally cooled RF ablation
system (Valleylab
TM, Boulder, Colorado, USA). All RF ablations
were performed by three gastroenterologists with ample experi-
ence of ablative techniques. The details of tumor ablation were
described previously [28].
Surgical removal of tumor
Tumors were completely resected, with a safety-margin of over
1 cm.
Follow-up studies
For the patients who received RFA, computed tomography or
magnetic resonance imaging was performed 3 weeks later to assess
whether the ablation was complete [28,29]. Following complete
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ultrasonography, chest X-ray, AFP, and blood biochemistry every
1 to 3 months in the first year and every 3 to 6 months thereafter.
Abnormal findings were verified by computed tomography or
magnetic resonance imaging. Intrahepatic recurrence was estab-
lished by the use of the criteria described elsewhere [30].
Depending on the location of the lesions as well as the condition
of the patient, extrahepatic recurrence was confirmed by biopsy,
aspiration cytology, computed tomography or magnetic resonance
imaging [30].
Statistics
Disease-free survival was measured from the date of diagnosis
to the date of recurrence, metastasis, death or last follow-up. The
Kaplan-Meier method was used to estimate the survival
probability, and the log-rank test was used to compare the
survival curves between groups. To determine the cutoffs of a
factor with parametric data, experimental univariate analysis was
performed to evaluate the association between the factor and
disease-free survival using a series of increasing values as the
cutoffs. This method was successfully used to identify clinical and
virological prognostic factors in HCC patients [30]. The
experimental cutoffs were calculated using the following formula:
the smallest value+n/156(the largest value – the smallest value)
(n=1 to 14). As such, a serial of cutoff values were generated for
each parametric factor. The experimental dichotomous groups
were thus separated by a cutoff at least 1/15 or at most 14/15 of
the factor range. This way of grouping was more readily to be
used for making treatment recommendations in the future. The
cutoff leading to the smallest P value was then selected for
subsequent Cox proportional hazard analysis. The justification as
well as the limitation of this minimum P-value approach in
clinical studies had also been discussed in a review [31]. Stepwise
Cox proportional hazard models were used to predict indepen-
dent predictors associated with disease-free survival. The results
are expressed as hazard-rate ratios (HRs) with 95% Confidence
interval (CI). In this study, the Bonferroni correction for multiple-
comparison was not applied on account of two reasons. First,
many of the factors included were known prognostic factors but
not randomly selected unknown factors. Our purpose was to
understand how significant the HUPR expression was in
comparison with these known factors. Second, our final goal
was to establish a combination scoring system. Therefore,
candidate factors that were possibly significant needed to be
included.
Statistical analysis was conducted using SPSS software (version
18.0).
Results
Clinical parameters
The baseline characteristics of the 97 patients are listed in
table 1. All of them belonged to the Barcelona Clinic Liver Cancer
(BCLC) stage A. HBV and HCV infection accounted for the
majority of our cases. Almost 90% of the patients were cirrhotic.
Most of the patients had abnormal liver function with the mean
AST and ALT levels higher than normal limits. However, only a
minority of the patients had severe complications (e.g., ascites:
11.3%), while the mean levels of albumin, bilirubin and
prothrombin time were within the normal limits. 75.3% of the
patients had solitary HCC and only 5.2% of the patients had
microvascular invasion. The tumor size ranged from 1.3 to 5.0 cm
in diameter. 81.4% of the patients received RFA, whereas the
remaining patients had tumors removed surgically. According to
the 6
th edition of AJCC/UICC TNM Classification, there were 69
and 28 patients belong to Stage I and Stage II respectively.
Expression of HURP in HCCs
Among the 97 patients included, positive expression of HURP
was found in the aspirated HCC cells of 19 patients (19.6%). Eight
representative cases in which the aspirated cells positively stained
with anti-HURP are shown in figure 1. HURP expression was
detected in over 80% of the aspirated cells in 15 patients and
expression was located in the cytoplasm of the HCC cells (figure 1,
lower panel). However, in the remaining 4 patients, ,50% of HCC
cells were positively stained (figure 1, upper panel). In 2 of these 4
patients, only a fewscattered HURP positiveHCCcells werefound.
To understand whether HURP expression was associated with
any of the clinicopathological parameters, logistic regression
analysis was performed. It was found that HURP expression was
not significantly associated with any clinicopathological parameter
(P.0.05 for all clinicopathological factors).
Association between clinical parameters and disease-free
survival
The association between clinical parameters and disease-free
survival is shown in table 2. Among the parameters, positive HURP
expression, cytological grading $3, AFP $35 ng/mL, bilirubin
$1.3 mg/dL, AST $50 U/L, and ALT $35 U/L were found to
be associated with a shorter disease-free survival (Figure 2).
Independent predictors of disease-free survival in the
stepwise multivariate Cox proportional hazard model
Using the stepwise multivariate Cox proportional hazard model,
4 factors remained as independent predictors for disease-free
Table 1. Basic clinical parameters for HCC patients.
Clinical parameters Value
Total number of patients 97
Gender-male, n (%) 62 (63.9%)
Age (years) 65.869.8
HBsAg-positive, n (%) 49 (50.5%)
Anti-HCV-positive, n (%) 42 (43.3%)
Alcoholism, n (%) 19 (19.6%)
Cirrhosis, n (%) 87 (89.7%)
RFA
a, n (%) 79 (81.4%)
Microvascular invasion
b, n (%) 5 (5.2%)
Ascites, n (%) 11 (11.3%)
Cytology grading ,3, n (%) 67 (69.1%)
Solitary tumor, n (%) 73 (75.3%)
Tumor size (diameter, cm) 3.1462.0
Alpha-fetoprotein (ng/mL) 53.66104.2
Albumin (g/dL) 3.760.5
Bilirubin (mg/dL) 1.160.7
Prothrombin time (seconds) 12.861.5
Creatinine (mg/dL) 1.461.8
AST (U/L) 58.0648.9
ALT (U/L) 49.1643.5
aOther patients had tumors removed surgically.
bPost-surgery specimens.
doi:10.1371/journal.pone.0026323.t001
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cytological grade $3, and tumor number .1. Their independence
was also verified by bivariate correlation tests. It is worth noting
that after adjusting for other confounding factors, the tumor
number (which is not a significant parameter for disease-free
survival in univariate analysis) became a significant factor in the
Cox proportional hazard model. The hazard ratio (HR), 95%
confidence interval (CI), and P values of the 4 independent
predictors are listed in table 3. Finally, we assigned a risk score to
each of the patients by calculating the number of independent
predictors carried by each patient. The risk scores ranged from 0
to 3, with no patient carrying all 4 factors (figure 3). Because no
significant difference was found in the disease-free survivals
between patients with risk score=0 and those with risk score=1
(Figure 3A, p=0.421), these two groups were merged (Figure 3B).
The disease-free survivals were significantly different among the
patients with risk scores #1, the patients with a risk score=2, and
the patients with a risk score=3 (Figure 3B). In contrast, no
difference (p=0.91) was noted between the recurrence-free
survivals of the 69 TNM stage I and 28 stage II patients.
Discussion
In general, hepatic resection was superior to RFA in HCCs
eligible for surgical removal, particularly for tumors .3 cm [32].
When treating patients with solitary HCC #3 cm, RFA has a
comparable recurrence free survival to surgical resection while
being less invasive [33]. However, hepatic resection remains the
treatment of choice for HCC in noncirrhotic patients because of
the well-preserved hepatic function in the residual liver. On the
other hand, RFA is safe and effective in managing HCC patients
with liver cirrhosis, and its high repeatability makes it particularly
valuable in controlling intrahepatic recurrences [34]. In two
prospective randomized controlled trials comparing RFA with
surgical resection, no significant difference was found in overall
survival or recurrence-free survival. Further, lower complication
rates were expectedly in patients treated with RFA [35,36].
Therefore, the choice of therapy in very early stage HCC should
depend on the patient’s suitability for surgery, the performance
status, the severity of liver cirrhosis, and the feasibility of RFA
given the location of the tumor [37]. In our series, patients
unsuitable for hepatectomy were subjected to RFA. Consistent
with previous reports, the disease-free survival between these two
methods was not significantly different (table 2). Thus, the bias of
the different treatment methods should be negligible.
The heterogeneous nature of HCC has greatly hindered the
search for effective molecular prognostic predictors. In a case-
control study of 39 hepatitis C virus-related HCC cases (24 early
stage) and 77 matched controls, neither des-gamma-carboxy
prothrombin nor AFP was able to predict optimally the emergence
of HCC [38]. Thus, even for HCC that has a homogeneous
underlying disease, a reliable biomarker has yet to be found.
According to the 6
th edition of AJCC/UICC TNM Classification,
69 and 28 BCLC stage A patients of the current study were
classified as stage I, and II, respectively. However, those patients
cannot be separated into prognosis distinguishable subgroups by
using AJCC/UICC TNM staging system. In the present study, we
demonstrated the independent prediction of disease-free survival
in HCC by HURP expression in aspirated HCC cells. HURP is
considered a stem cell marker and is undetectable in fully
differentiated cells [39]. Similar to this observation, another stem
cell marker, epithelial cell adhesion molecule (EpCAM), was found
to be expressed dominantly in confluent multinodular type HCC
and EpCAM expression levels predicted the recurrence of HCC
[40]. Additionally, overexpression of Aurora B, a chromosomal
passenger protein involved in chromosome segregation, spindle-
checkpoint, and cytokinesis [41], independently predicted tumor
invasion and poor prognosis of HCC [42]. The functional
similarity between HURP and Aurora B further supports the
predictive role of HURP in disease-free survival of HCC.
In recent years, tumor cell seeding along the needle tract has
been found to be a risk associated with liver biopsy [43]. Fine
needle aspiration cytology has proven to be a safe and accurate
alternative for liver biopsy to identify the vast majority of HCC
[44]. Therefore, HURP staining in aspirated HCC cells can
potentially develop into a convenient method for predicting
disease-free survival of HCC. However, there are some limitations
associated with this technique. While HURP is named for its gene
being up-regulated in human HCC, only 19.5% (19/97) of our
HCC aspirated samples showed positive HURP expression. It is
possible that in the remaining samples, the expression levels of
Figure 1. Immunohistochemistry analysis for HURP expression in aspirated human HCC cells in 8 representative cases. HURP was
stained in brown color.
doi:10.1371/journal.pone.0026323.g001
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Probably in these samples, the majority of HCC cells were in
nonproliferating ‘out-of-cycle’ states. This caused the tumors to
grow slowly, which resulted in a longer disease-free survival.
Alternatively, in view of the assumption that HURP could be a
stem cell marker, the low prevalence of HURP-positive cells in this
study might reflect the fact that most of our HCCs arose from
inflammation-related mutation induced by viral insults to
hepatocytes (HBV or HCV infection in our series was over
90%), whereas HCCs that develop from de novo mutation of the
naive hepatic stem cells only accounted for a minority of cases. In
this study, we demonstrated that high AST, ALT, and bilirubin
levels correlate with a shorter disease-free survival. This suggests
that virus related hepatic necroinflammation plays an important
role in HCC recurrence. At this time, it is not clear whether there
is a pathway for the HCC cells that develop from virus related
hepatocyte damage to evolve into HCCs with the signature of
cancer stem cells. Finally, as mentioned in the introduction,
redundant pathways that can compensate for HURP function
have been proposed. As such, for HCCs that lack HURP
Table 2. Association between clinical parameters and disease-free survival.
Parameters Category No. of patients Disease-free survival (months) P (Log Rank)
Mean 95% CI
HURP expression Negative 78 21.9 18.9–24.7 0.023
Positive 19 14.1 10.2–18.1
Treatment RFA 79 20.2 17.4–23.1 0.770
Surgical 18 19.4 14.7–24.3
Sex Female 35 21.1 16.7–25.4 0.772
Male 62 19.4 16.5–22.3
Age ,65 years 45 22.6 18.9–26.3 0.105
$65 years 52 17.1 14.2–20.0
HBsAg Negative 48 17.9 14.8–21.1 0.353
Positive 49 21.5 17.9–25.0
Anti-HCV Negative 55 20.3 16.8–23.8 0.979
Positive 42 18.9 15.6–22.2
Alcoholism No 78 20.8 17.8–23.8 0.606
Yes 19 17.9 13.7–22.1
Cirrhosis No 10 19.4 15.2–23.6 0.910
Yes 87 20.4 17.7–23.3
Cytological grading ,3 67 22.6 19.7–25.7 0.008
$3 30 14.7 11.1–18.3
Tumor number Solitary 73 21.1 18.1–24.0 0.342
.1 24 17.0 12.8–21.3
Tumor size (diameter) ,3 cm 61 20.6 17.5–23.8 0.823
$3 cm 36 18.8 14.8–22.7
Ascites Absence 86 20.0 17.2–22.7 0.435
Presence 11 21.9 16.3–27.4
Alpha-fetoprotein ,35 ng/mL 69 22.0 19.0–25.1 0.039
$35 ng/mL 28 15.2 11.4–18.9
Albumin ,4 g/dL 55 19.8 16.2–23.4 0.578
$4 g/dL 42 20.5 17.2–23.8
Bilirubin ,1.3 mg/dL 73 21.3 18.7–23.9 0.010
$1.3 mg/dL 24 15.1 10.0–20.3
Prothrombin time ,12 sec 35 19.8 16.5–23.2 0.902
$12 sec 62 20.8 17.3–24.2
Creatinine ,1.0 mg/dL 48 21.7 18.1–25.4 0.391
$1.0 mg/dL 49 18.7 15.5–21.9
AST ,50 U/L 59 23.5 20.3–26.8 0.003
$50 U/L 38 15.2 11.7–18.8
ALT ,35 U/L 43 25.3 21.5–29.0 0.005
$35 U/L 54 16.5 13.7–19.4
doi:10.1371/journal.pone.0026323.t002
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over-expression are highly plausible.
Another puzzling aspect of the present data is that almost all
HURP expression localized in the cytoplasm of the HCC cells.
Importin-a1 was shown to be an independent predictor of early
recurrence after HCC resection [45]. HURP is one of the spindle
assembly factors whose activity is regulated by importins, and the
steady-state distribution of HURP is determined by the continuous
shuttling of HURP between the cytoplasm and nucleus via
importin [46]. Most HURP studies have focused on its spindle
assembly role in the nucleus during mitosis, while little is known
regarding its function in the cytoplasm during interphase. Both
HURP and Importin-a1 are over-expressed in HCCs with poor
prognosis, which suggests important roles for these molecules in
oncogenesis. The aberrant cytoplasmic over-expression of HURP
in HCC might implicate an unexplored function in cell cycle
regulation that demands further clarification.
Aside from HURP positivity, AST $50 U/L, cytological grade
$3, and tumor number .1 were also found to be independent
predictors for the disease-free survival in our HCC patients.
Cytological grading represents the differentiation of the HCC cells
and the tumor number may indicate a uni- or multi-focal tumor
origin or alternatively, the staging of HCC. These factors are all
suggestive of poor prognosis and have been documented by several
studies [47,48]. AST, ALT, bilirubin and AFP levels, which were
identified to be significant prognosis predictors in univariate
analysis, reflected either the degree of inflammation (AST, ALT
and bilirubin) or the tumor burden (AFP). AFP also reflected the
degree of hepatic inflammation in some cases [49]. In the
literature, several lines of evidence indicate that hepatic inflam-
mation is a prognostic predictor for HCC. The preoperative CRP
level was shown to be associated with the aggressiveness of early
recurrent HCC in a study of 124 patients who underwent
hepatectomy [50]. In addition, studies regarding HCV-related
HCC have shown that HCC almost always develops in a
histologically abnormal liver and that the mere existence of
chronic liver disease represents a potential risk for the develop-
ment of HCC [51]. Indeed, chronic hepatic necroinflammation
with its subsequent generation of reactive oxygen species can
induce chromosomal mutations and eventually malignant trans-
formation of proliferating hepatocytes. Likewise, poor liver
function reserve, suggested by hyperbilirubinemia, was noted to
be significantly associated with HCC occurrence in other studies
[52]. A study enrolling 150 patients with a single HCC smaller
than 5 cm in diameter treated by particle radiotherapy found that
Child-Pugh classification was an independent risk factor for local
recurrence [53]. Finally, in a retrospective study composed of 413
cirrhotic HCC patients receiving RFA and 648 cirrhotic HCC
patients receiving surgical resection, serum AFP was found to be
Table 3. Independent predictors of disease-free survival in
the stepwise multivariate Cox proportional hazard model.
Factors HR 95%CI P
HURP-positive in HCC cells 2.334 1.165–4.679 0.017
AST $50 U/L 3.697 1.868–7.319 ,0.001
Cytological grade $3 4.249 2.061–8.759 ,0.001
Tumor number .1 2.633 1.212–5.722 0.014
doi:10.1371/journal.pone.0026323.t003
Figure 2. Comparison of the disease-free survivals between HCC patients with and without a statistically significant
clinicopathological feature. n, number of HCC patients at risk.
doi:10.1371/journal.pone.0026323.g002
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By combing the 4 independent predictors, which had been directly
or indirectly associated with the prognosis of HCC in the
literature, the risk scores of the patients with HCC separated the
patients into three distinct groups with significantly different post-
therapy prognoses. Therefore, in patients with BLCL stage A, risk
scores that incorporate HURP staining are capable of providing
further distinctions between different post-therapeutic prognosis
groups. The small sample size of the present study, however,
limited its clinical value. To validate the prognostic significance of
HURP expression in a larger HCC cohort, a multi-center study
would be extremely informative and should be conducted in the
future.
To our knowledge, this is the first study regarding the clinical
application of HURP expression in predicting the disease-free
survival of HCC patients. A new risk score, composed of 4
independent predictors including HURP positivity in HCC cells,
AST $50 U/L, cytological grade $3, and tumor number .1,
separated HCC patients with BCLC stage A into three prognosis-
distinguishable groups. These findings may be valuable in
assessing the effects of therapeutic interventions for HCC patients
with BCLC stage A, which is the most common stage discovered
due to the early detection of HCC via orderly tumor survey.
Finally, personalized therapy and follow-up for patients with early
stage HCC can be pursued in the near future.
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